Foghorn Therapeutics (FHTX) News Today $4.39 +0.07 (+1.62%) Closing price 04:00 PM EasternExtended Trading$4.39 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $12.13June 7, 2025 | americanbankingnews.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Buy" by BrokeragesFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has been given an average rating of "Buy" by the eight brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating onJune 4, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Position Boosted by Point72 Asset Management L.P.Point72 Asset Management L.P. lifted its stake in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 58.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 634,761 shares of the company's stock after purchasing an additional 235,059 sMay 23, 2025 | marketbeat.comFoghorn Therapeutics to Participate in Four Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comQ2 EPS Estimate for Foghorn Therapeutics Cut by AnalystFoghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - B. Riley decreased their Q2 2025 EPS estimates for shares of Foghorn Therapeutics in a report issued on Wednesday, May 14th. B. Riley analyst K. Patel now expects that the company will post earnings of ($0.36) per share for the quarter, downMay 20, 2025 | marketbeat.comWedbush Expects Weaker Earnings for Foghorn TherapeuticsFoghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Analysts at Wedbush dropped their Q2 2025 earnings per share estimates for Foghorn Therapeutics in a report issued on Wednesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.31) per share forMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX)Jacobs Levy Equity Management Inc. raised its holdings in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 73.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 223,780 shares of the company's sMay 19, 2025 | marketbeat.comFoghorn Therapeutics Provides First Quarter 2025 Financial and Corporate UpdateMay 14, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have assignedMay 12, 2025 | marketbeat.comDAFNA Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX)DAFNA Capital Management LLC grew its holdings in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 395.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 186,717 shares of the company's stock after acquiring an aMay 10, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Raises Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX)Deerfield Management Company L.P. Series C lifted its stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,255,514 shares of the company's stock after purchasing an additioMay 10, 2025 | marketbeat.comFoghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdlesMay 7, 2025 | investing.comFoghorn Therapeutics to Participate in the Citizens Life Sciences ConferenceMay 5, 2025 | globenewswire.comFoghorn Therapeutics expands board with biotech veteransMay 3, 2025 | investing.comFoghorn Therapeutics (NASDAQ:FHTX) Receives "Market Outperform" Rating from JMP SecuritiesJMP Securities reiterated a "market outperform" rating and set a $9.00 target price on shares of Foghorn Therapeutics in a research note on Wednesday.May 2, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $13.00 price target on shares of Foghorn Therapeutics in a research note on Wednesday.May 2, 2025 | marketbeat.comFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsMay 1, 2025 | globenewswire.comFoghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on MondayFoghorn Therapeutics (NASDAQ:FHTX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-foghorn-therapeutics-inc-stock/)April 30, 2025 | marketbeat.comFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline UpdateApril 28, 2025 | globenewswire.comFoghorn Therapeutics (NASDAQ:FHTX) Now Covered by Analysts at JMP SecuritiesJMP Securities began coverage on shares of Foghorn Therapeutics in a research note on Wednesday. They set a "market outperform" rating and a $9.00 price target on the stock.April 25, 2025 | marketbeat.comJMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform RecommendationApril 23, 2025 | msn.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of "Buy" from AnalystsShares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have earned an average recommendation of "Buy" from the six brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one hasApril 16, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher - Time to Buy?Foghorn Therapeutics (NASDAQ:FHTX) Trading Up 4.1% - Here's What HappenedApril 16, 2025 | marketbeat.comFoghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual MeetingApril 15, 2025 | globenewswire.comFoghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC PatientsMarch 26, 2025 | seekingalpha.comFoghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR MeetingMarch 25, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from BrokeragesFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendatMarch 22, 2025 | marketbeat.com2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,029,383 shares of the company's stock, valued at approxMarch 22, 2025 | marketbeat.comWhat is B. Riley's Forecast for FHTX Q1 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings estimates for Foghorn Therapeutics in a research note issued on Thursday, March 13th. B. Riley analyst K. Patel forecasts that the company will earn ($0.34) per share for tMarch 17, 2025 | marketbeat.comFoghorn Therapeutics' (FHTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Foghorn Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPSFoghorn Therapeutics (NASDAQ:FHTX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.13.March 7, 2025 | marketbeat.comFoghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic OutlookMarch 6, 2025 | globenewswire.comInstitutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year lossesFebruary 28, 2025 | finance.yahoo.comFoghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on ThursdayFoghorn Therapeutics (NASDAQ:FHTX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comFoghorn Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been given an average rating of "Buy" by the six brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, four have issued a buy recommenFebruary 24, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short InterestFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 918,000 shares, a growth of 9.1% from the January 15th total of 841,700 shares. Based on an average daily volume of 159,900 shares, the days-to-cover ratio is presently 5.7 days. Currently, 3.5% of the shares of the stock are short sold.February 18, 2025 | marketbeat.comWhat is B. Riley's Estimate for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at B. Riley issued their FY2024 earnings per share (EPS) estimates for shares of Foghorn Therapeutics in a report issued on Wednesday, January 29th. B. Riley analyst K. Patel expects that the company will post earnings pFebruary 3, 2025 | marketbeat.comB. Riley Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Strong-Buy"B. Riley raised shares of Foghorn Therapeutics to a "strong-buy" rating in a research report on Wednesday.January 31, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy RecommendationJanuary 30, 2025 | msn.comFoghorn Therapeutics a new buy at B Riley on tumor fighting technologyJanuary 30, 2025 | msn.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Rating of "Moderate Buy" by BrokeragesShares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assignedJanuary 30, 2025 | marketbeat.comB.Riley sets Foghorn stock Buy rating, $10 targetJanuary 30, 2025 | msn.comFoghorn Therapeutics initiated with a Buy at B. RileyJanuary 30, 2025 | markets.businessinsider.comOptimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic DevelopmentsJanuary 30, 2025 | markets.businessinsider.comFoghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. RileyB. Riley began coverage on Foghorn Therapeutics in a research report on Thursday. They issued a "buy" rating and a $10.00 target price for the company.January 30, 2025 | marketbeat.comFoghorn Therapeutics files $300M mixed securities shelfJanuary 25, 2025 | markets.businessinsider.comFoghorn Therapeutics highlights strategic objectives for 2025January 13, 2025 | markets.businessinsider.comFoghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025January 13, 2025 | finance.yahoo.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC lifted its holdings in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 27.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 677,386 shares of the company's stock after buying an additional 146,276 sharesJanuary 4, 2025 | marketbeat.com Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address FHTX Media Mentions By Week FHTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼1.870.90▲Average Medical News Sentiment FHTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼12▲FHTX Articles Average Week Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Akebia Therapeutics News Today CureVac News Today Enliven Therapeutics News Today Phibro Animal Health News Today Collegium Pharmaceutical News Today Avadel Pharmaceuticals News Today CorMedix News Today Nurix Therapeutics News Today Syndax Pharmaceuticals News Today Pharvaris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FHTX Stock Free FHTX Stock Alerts